Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of potassium ATP channel regulator in preparation of medicine for resisting diabetic nephropathy

A technology for diabetic nephropathy and anti-diabetes, which is applied in the field of chemical medicine of potassium ATP channel regulators, can solve problems such as unknowing, and achieve the effect of reducing urinary microalbumin

Pending Publication Date: 2021-12-03
HANGZHOU QIAN BIOTECHNOLOGY LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] According to the search by the applicant, there is no literature report on K ATP The correlation between channel agonists and the treatment of diabetic nephropathy has not been reported in the literature K ATP Channel openers (such as diazoxide, krocarin, pinacidil, nicandil, apcarline, etc.) can be used in the treatment of diabetic nephropathy; Whether it is effective in the early stages of diabetic nephropathy is unknown to those skilled in the art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of potassium ATP channel regulator in preparation of medicine for resisting diabetic nephropathy
  • Application of potassium ATP channel regulator in preparation of medicine for resisting diabetic nephropathy
  • Application of potassium ATP channel regulator in preparation of medicine for resisting diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1 Establishment of Diabetic Nephropathy Model and Drug Detection Method

[0080] 1. Establishment of diabetes model

[0081] Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic β cell line, INS1[J]. International Union of Biochemistry and Molecular Biology Life.1996,39(6):1229-1236.), the pathophysiological characteristics of the rats modeled by STZ are relatively close to those of humans, and blood sampling can be repeated to monitor index changes, and sufficient Kidney tissue for subsequent histological section analysis. Therefore, STZ was chosen to create a diabetic rat model. In addition, due to the high toxicity of STZ, the model can be better established by multiple injections at low doses. After modeling, a high-fat diet was administered every day until the end of the experiment. High-fat diet can induce diabetic nephropathy in STZ rats.

[0082] See Embodiment 2 for the specific modeling method.

...

Embodiment 2

[0109] Embodiment 2 studies the impact of diazoxide on diabetic nephropathy

[0110] 【Purpose】

[0111] On the basis of the rat model of diabetic nephropathy constructed in Example 1 and the detection method, this example aims to investigate whether high, medium and low doses of diazoxide have a therapeutic effect on diabetic nephropathy.

[0112] 【experimental method】

[0113] After 7 days of adaptive feeding of SD rats, 10 SD rats were randomly selected as a blank control group (Group A), that is, no injection of STZ. The remaining 65 rats were randomly divided into 4 groups, 14 of which were the negative control group, and 17 rats in each group. After feeding high-fat diet for 2 weeks to induce insulin resistance, the diabetes model was established. The specific modeling method is as follows:

[0114](1) After fasting for at least 12 hours, inject STZ at a dose of 30 mg / kg, and eat and drink freely after injection;

[0115] (2) Measure the fasting blood glucose 48 hours ...

Embodiment 3

[0145] Embodiment 3 studies the remaining K ATP Effect of agonists on diabetic nephropathy

[0146] 【Purpose】

[0147] On the basis of the diabetic nephropathy rat model and detection method constructed in Example 1, this example aims to investigate the remaining K ATP Whether agonists have a therapeutic effect on diabetic nephropathy.

[0148] 【experimental method】

[0149] After 130 SD rats were adaptively fed for 7 days, 10 were randomly selected as the blank control group, that is, no injection of STZ. The remaining 120 rats were randomly divided into 8 groups (comprising: negative control group, 1mg / Kg krocarin group, 1mg / Kg pinacidil group, 0.5mg / Kg nicodinil group, 1mg / Kg apuka Lin group, 1mg / Kg quinetazolone group, 0.5mg / Kg minoxidil group, 5mg / Kg nigudipine group), 15 rats in each group, after feeding with high-fat diet for 2 weeks to induce insulin resistance, start to establish Diabetes model, the specific modeling method and detection method are the same as in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel pharmaceutical application of a potassium ATP channel regulator, namely application of the potassium ATP channel regulator (such as diazoxide, crocarine, pinadil, niacdil, alplecarine and the like) in preparation of a medicine for resisting diabetic nephropathy. The invention further provides application of a pharmaceutical composition taking the potassium ATP channel regulator as an active ingredient in prevention or treatment of diabetic nephropathy. A diabetic rat is modeled through streptozotocin (STZ), high fat diet is given to the rat after modeling to form the diabetic nephropathy, whether the rat enters the diabetic nephropathy or not is detected by taking microalbuminuria (mALB) as an index, and whether the model succeeds or not is observed by taking the weight and blood sugar level of the rat as indexes. Experimental results show that after the potassium ATP channel opener such as diazoxide is administered to the diabetic rat, the renal injury process of the diabetic rat can be delayed.

Description

technical field [0001] The present invention relates to potassium ATP (K ATP ) The technical field of chemical medicine of channel modulator, be specifically related to a kind of K ATP The new pharmaceutical application of the channel modulator, that is, the application of the potassium ATP channel modulator in the preparation of anti-diabetic nephropathy drugs. Background technique [0002] Diabetic Kidney Disease (DKD) is one of the most important microvascular complications of diabetes, the main cause of chronic kidney disease, and the most common disease leading to end-stage renal disease (ESRD). In fact, most diabetic patients who die from cardiovascular disease also have diabetic nephropathy, and the cause of death is strongly associated with diabetic nephropathy (Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk type 2diabetes [J]. Journal of the American Society of Nephrology. 2013,24(2):...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/549A61P3/10A61P13/12
CPCA61K45/00A61K31/549A61P3/10A61P13/12
Inventor 陈渊朱江
Owner HANGZHOU QIAN BIOTECHNOLOGY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com